Skip to content

Ganciclovir

Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Also known as: denosine, ganciclovir sodium, gancyclovir, hydroxyacyclovir, natclovir

OfpFDA approvedOrphan designationATC J05AB06ATC S01AD09

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Ganciclovir is an ofp drug in the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1989. Its mechanism of action is classified as DNA Polymerase Inhibitors. DrugCentral lists 7 molecular targets, including UL26, GRM1 and VCP. Recorded indications include CMV Retinitis in AIDS Patients, CMV Retinitis in Immunocompromised Patients, Cytomegaloviral retinitis and Herpes simplex dendritic keratitis.

  • Approval status: ofp (first approved 1989 by the FDA).
  • Drug class: Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor; Nucleoside Analog Antiviral.
  • Mechanism of action: DNA Polymerase Inhibitors.
  • Molecular targets: UL26, GRM1, VCP and GRM5 (7 listed in DrugCentral).
  • Indications: CMV Retinitis in AIDS Patients, CMV Retinitis in Immunocompromised Patients, Cytomegaloviral retinitis, Herpes simplex dendritic keratitis and Myocardial Perfusion Imaging Adjunct and others.
  • ATC code: J05AB06 (Nucleosides and nucleotides excl. reverse transcriptase inhibitors).
  • Molecular formula: C9H13N5O4; molecular weight 255.23 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (11)

  • CMV Retinitis in AIDS Patients
  • CMV Retinitis in Immunocompromised Patients
  • Cytomegaloviral retinitis
  • Herpes simplex dendritic keratitis
  • Myocardial Perfusion Imaging Adjunct
  • Paroxysmal supraventricular tachycardia
  • Prevention of CMV Disease After Cardiac Transplantation
  • Prevention of CMV Disease After Kidney Transplantation
  • Prevention of CMV Disease After Kidney-Pancreas Transplantation
  • Prevention of CMV Disease After Organ Transplant
  • Prevention of CMV Disease in Advanced HIV Patients

Off-label uses (4)

  • CMV-Related Polyradiculopathy in AIDS Patients
  • Cytomegalovirus infection
  • Prevention of Cytomegalovirus Disease
  • Supraventricular tachycardia

Contraindications (37)

  • Acute cerebrovascular insufficiency
  • Acute coronary syndrome
  • Acute nephropathy
  • Anemia
  • Aortic valve stenosis
  • Aplastic anemia
  • Asthma
  • Bilateral cataracts
  • Breastfeeding (mother)
  • Chronic obstructive lung disease
  • Complete atrioventricular block
  • Dehydration
  • Disorder of autonomic nervous system
  • Endophthalmitis
  • Eye infection
  • Granulocytopenic disorder
  • Hypovolemia
  • Kidney disease
  • Left main coronary artery disease
  • Left to right cardiovascular shunt
  • Low blood pressure
  • Mitral valve stenosis
  • Neutropenic disorder
  • Pericarditis
  • Pulmonary emphysema
  • Reduced visual acuity
  • Respiratory alkalosis
  • Respiratory insufficiency
  • Retinal detachment
  • Second degree atrioventricular block
  • + 7 more

Mechanism & targets

Mechanism of action (MoA)DNA Polymerase Inhibitors
Established pharmacologic classCytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor; Nucleoside Analog Antiviral

Molecular targets (7)

TargetGeneActionActivity
Capsid scaffolding proteinUL26unknownEC50 6.07
Metabotropic glutamate receptor 1GRM1unknownKi 6.05
Transitional endoplasmic reticulum ATPaseVCPunknownIC50 5.89
Metabotropic glutamate receptor 5GRM5unknownKi 5.41
Purine nucleoside phosphorylasepunAunknownKd 4.80
DNA polymerase catalytic subunit—inhibitor—
Thymidine kinaseTKunknown—

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1989-06-23FDA—ROCHE PALOYes

ATC classification

ATC codeTherapeutic hierarchy
J05AB06ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Nucleosides and nucleotides excl. reverse transcriptase inhibitors
S01AD09SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFECTIVES › Antivirals

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Cytomegalovirus infection2052.5
Drug resistance1748.0
Cytomegalovirus viraemia999.6
Cytomegalovirus infection reactivation849.6
Pathogen resistance838.8
Off label use715.4
Multiple organ dysfunction syndrome700.3
Post transplant lymphoproliferative disorder667.3
Pancytopenia636.3
Graft versus host disease541.1
Pneumonia cytomegaloviral529.1
Cystitis haemorrhagic512.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ganciclovir is on its molecule page.

Molecular formulaC9H13N5O4
Molecular weight255.23 g/mol
CAS number82410-32-0
InChIKeyIRSCQMHQWWYFCW-UHFFFAOYSA-N
PubChem CID135398740
NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ganciclovir used for?

DrugCentral lists the following indications for Ganciclovir: CMV Retinitis in AIDS Patients, CMV Retinitis in Immunocompromised Patients, Cytomegaloviral retinitis, Herpes simplex dendritic keratitis, Myocardial Perfusion Imaging Adjunct, Paroxysmal supraventricular tachycardia, Prevention of CMV Disease After Cardiac Transplantation and Prevention of CMV Disease After Kidney Transplantation and others.

How does Ganciclovir work?

Ganciclovir is classified as DNA Polymerase Inhibitors; its molecular targets in DrugCentral include UL26, GRM1, VCP and GRM5.

When was Ganciclovir first approved?

Ganciclovir was first approved by the FDA in 1989.

What drug class does Ganciclovir belong to?

Ganciclovir is in the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor class.

What is the chemical formula of Ganciclovir?

Ganciclovir has the molecular formula C9H13N5O4 and a molecular weight of 255.23 g/mol.

Browse: all drugs starting with G · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval1989-06-23
AgencyFDA
Targets7
Indications11
FormulaC9H13N5O4
DrugCentral ID1277
Interactive profile